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Abstract- Alzheimer’s disease (AD) is a disorder with multiple pathophysiological causes, destructive 
outcomes, and no available definitive cure. Pelargonidin (Pel), an anthocyanin derivative, is an estrogen 
receptor agonist with little estrogen side effects. This study was designed to assess Pel memory enhancing 
effects on the a rat Amyloid Beta25-35 (Aβ) intrahippocampal microinjections model of AD in the passive 
avoidance task performance paradigm and further evaluate the potential estrogen receptor role on the 
memory-evoking compound. Equally divided rats were assigned to 5 groups of sham, Aβ intrahippocampal 
microinjected, Pel pretreated (10 mg/kg; P.O), α estrogen antagonist intra-cerebrovascular (i.c.v.) 
microinjected, and β estrogen antagonist (i.c.v) microinjected animals. Intrahippocampal microinjections of 
Aβ were adopted to provoke AD model. Passive avoidance task test was also used to assess memory 
performance. Pel pretreatment prior to Aβ microinjections significantly improved step-through latency 
(P<0.001) in passive avoidance test. In α and β estrogen, antagonists received animals, passive avoidance task 
performance was not statistically changed (P=0.11 & P=0.41 respectively) compared to Pel pretreated and 
sham animals. Our results depicted that Pel improves Aβ induced memory dysfunction in passive avoidance 
test performance through estrogen receptor independently related pathways.  
© 2016 Tehran University of Medical Sciences. All rights reserved.  
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Alzheimer’s disease is a brain neurodegenerative 
ailment and the commonest cause of dementia. It usually 
affects memory performance, language, problem-solving 
activities and cognitive learning and disturbs normal 
personal life. Patients, in the end, stages of the disease 
would be bed-ridden and require full care services until 
their early death (1). More than 35 million people 
around the globe were affected (2). Based on informal 
data adapted from Iran Alzheimer’s Association around 
300,000 up to 450,000 people are suffering from the 
disease. The medial temporal lobe region, such as 
hippocampus is mostly undergone synaptic changes and 
neuronal damage during the disease course. It can lead 
to death within 3 to 9 years post medical diagnosis (2,3). 
The disease is a leading health care and social problem 
with few palliative treatments and means of diagnosis 
but post-mortem brain biopsy (4). 
Apart from deranged mechanisms such as 
mitochondrial dysfunction, mitotic changes, and genetic 
components, many other pathophysiological defects 
have also been identified in the course of the disease. 
The pathophysiology of AD is intricate and includes 
several neurotransmitter systems and pathophysiological 
processes. However 3 hallmarks are most prominent 
which involve β amyloid plaques, neurofibrillary 
tangles, and neuronal cell death. Several challenging 
hypotheses have been designed to explain the disease 
basic cause which are amyloid hypothesis, tau 
hypothesis, cholinergic hypothesis, oxidative stress 
hypothesis, glutamatergic hypothesis, cholesterol, 
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chronic inflammation and other neurotransmitter 
deficiencies (5), but misfolded proteins accumulated in 
the aging brain is the core neuropathological hallmark 
which results in oxidative and inflammatory damage 
followed by energy failure and synaptic dysfunction 
(2,6). Among all molecular defects, the Aβ peptides 
have long been said to play a pivotal role in the 
pathogenesis and progression of the disease and “ 
amyloid cascade hypothesis” has received most 
investigators’ attention (7). It appears that cellular 
adaptive strategy to oxidative stress in response to 
amyloid beta production is becoming the dominant 
hypothesis in the literature (8).  
Despite noticeable advances in AD’s 
pathophysiology and therapeutic knowledge, only four 
anticholinesterase drugs plus memantine have been 
approved by US Food and Drug Administration for 
symptomatic treatment due to the complicated nature of 
the disease (9). Accordingly, researchers have turned 
their focus to new types of therapeutical modalities. 
Among disparate options, flavonoid-based sources like 
anthocyanins have received particular focus because of 
their high oral intake in humans and multiple health 
promoting effects such as improving motor function, 
antiviral, vasoprotective, antiangiogenic activity, 
hippocampal neuroplasticity, proteasome inhibition, 
protein misfolding and aggregation prevention (10), 
antiatherogenic properties (11), anti-inflammatory, 
antioxidant (12), anti-adhesive, estrogenic/antiestrogenic 
activity, angiotensin-converting enzyme inhibitory 
properties (13), antihyperglycemic activity (14) and 
ocular preventive and protective effects (15). 
Anthocyanins are water-soluble pigments largely 
found in red, purple, and blue colored plant tissues (16). 
Pelargonidin (Pel), an anthocyanin with above-
mentioned flavonoid’s useful properties plus efficient 
absorption from the gastrointestinal tract (17), blood-
brain accessibility (18), non-genotoxicity, tremendous 
efficacy, reasonable price (19), neural protection (20), 
antihyperglycemic activity (21) and anti-thrombosis 
function (22) grabbed our attention to design an 
introductory study to investigate the possible memory 
enhancing role of oral Pel pretreatment in an 
intrahippocampal Amyloid Beta25-35 rat model of AD. 
 
Materials and Methods 
 
Animals 
Forty locally bred male Wistar rats weighing 280-
320 g were identically divided into five groups and kept 
at the animal house with free access to standard chow 
and tap water at 21 ± 2 ºC, relative humidity of 45 ± 15 
% and 12 hours light/dark cycle. Passive avoidance task 
test accomplished from 8 a.m. till 4 p.m. All procedures 
for care and use of animals conducted in accordance 
with Tehran University of Medical Sciences regulations 




Rats were equally divided into 5 groups of sham, 
Aβ25-35 intrahippocampal microinjected (Aβ), Pel 
pretreated (10 mg/kg; P.O) (Aβ + Pel), α estrogen 
antagonist intra-cerebrovascular (i.c.v) microinjected 
(Aβ + Pel + Anti Eα), and β estrogen antagonist intra-
cerebrovascular microinjected (Aβ + Pel + Anti Eβ) 
animals. 
Stereotaxic surgery was done under general 
anesthesia upon intraperitoneal ketamine (100 mg/kg) 
and xylazine (5 mg/kg) mixture administration. After 
anesthesia induction, the animal head was symmetrically 
held in Stoelting stereotaxic instrument to achieve skull 
flat position. The scalp skin was clean shaved and 
scrubbed with a solution of 10% povidone-iodine. A 
midline incision was made. Two burr holes were 
symmetrically made with a micro drill over the skull at 
coordinates of -3.5 mm posterior to the bregma, ± 2 mm 
lateral to the sagittal suture and 2.8 mm ventral to dura 
matter, based on the rat brain in stereotaxic coordinates 
(23) for bilateral amyloid beta25-35 fragment, vehicle or 
saline microinjections. Pel (10 mg/kg, Sigma-Aldrich 
Chemicals, USA) in chromophore as a solvent was 
orally administered once a day for three days through a 
stainless steel ball-tipped feeding needle. The last dose 
was taken one hour prior to the stereotaxic procedure 
based on the pilot and our earlier studies (21). In Aβ 
microinjected animals, 2 µl of an Aβ25-35 (5 µg/µl) 
solution prepared in normal saline with pH = 8, 
preincubated at 37 ºC for 72 hours, bilaterally 
microinjected into dorsal hippocampus. In sham-
operated rats, normal saline was microinjected 
accordingly. 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-
(2-piperidinylethoxy)phenol]-1H-pyrazole 
dihydrochloride (MPP), α estrogen receptor antagonist 
(Anti Eα) and 4-[2-Phenyl-5,7-
bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-
yl]phenolas (PHTPP), as β estrogen receptor antagonist 
(Anti Eβ) were dissolved in dimethyl sulfoxide (DMSO) 
and diluted with aCSF (Merck Chemical, Germany). 
Prepared solutions (10 μg/rat) were i.c.v injected at a 
volume of 5 μl at coordinates -1 mm posterior to the 
bregma, 1.5 mm lateral to the midline and 4 mm ventral 
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to dura matter under general anesthesia 30 min post-Pel 
gavage. Aβ25-35 (5 µg/µl) was also bilaterally 
microinjected into the posterior hippocampus 30 min 
after i.c.v microinjection of the blockers at the 
mentioned coordinates. Passive avoidance test was then 
carried out after surgical recovery by an observer blind 
to the experimental groups. 
 
Passive avoidance test 
Passive avoidance is a fear-motivated test to study 
long and short term memories in an associative manner. 
It needs the animal to behave opposite to its innate dark 
preference. The test was started on day 24 post-surgery 
using the shuttle-box apparatus consisting of two 
compartments isolated with a retractable door. One 
compartment lit with a bright cold house light as the safe 
compartment while the other made from dark opaque 
walls and roof as unsafe side. The floor in both 
compartments made of metal shocking grids except that 
in unsafe side the floor wired to receive an electric 
shock of 1mA intensity for 1-second duration.  
In this test, each animal kept on the dark side at least 
10 min to adapt to the darkened compartment for the 
first two days. On the third day, the animal again put on 
the safe side while the retractable door was closed. 
Then, the light in the safe compartment was turned on, 
and the retractable door was opened to measure the 
initial latency (IL). As soon as the animal’s tail tip 
crossed the border line on the safe side and the unsafe 
side, the retractable door released and an electric shock 
of 1mA was applied to the animal limbs through the 
floor grids. After the shock delivery, the animal returned 
to its cage for the test session. On day 27, the testing 
trial was done just like the day before, except that no 
foot shock applied, and the step-through latency (STL) 
measured. In this test, a 450 seconds cut-off time was 
established if the animal did not cross the border. 
 
Statistical analysis 
Data analysis was performed using SPSS 20 
statistical software. Data were analyzed with Kruskal-
Wallis non-parametric test. In all statistical analysis, 




Data expressed in figure 1 demonstrates respective 
STL of passive avoidance memory in experimental 
groups. As noted, no statistical differences were found 
among IL of the experimental groups. 
 
 
Figure 1. Passive avoidance task illustrates step through latency among the experimental animals 
Bilateral CA1microinjectios of saline 2μl (Sham), Aβ25-35 5μg (Aβ) , Aβ25-35 + Pelargonidin 10 mg/kg (Pel) orally fed for 3 consecutive 
pretreatment days (Aβ + Pel), Aβ 25-35 + Pel orally fed for 3 consecutive pretreatment days + unilateral intra cerebroventricular (i.c.v.) microinjection 
of  α estrogen receptor antagonist (Aβ + Pel + Anti Eα), Aβ25-35 + Pel orally fed for 3 consecutive pretreatment days + unilateral i.c.v, microinjection 
of β estrogen receptor antagonist (Aβ + Pel + Anti Eβ). 
 
However, STL was profoundly lowered in Aβ treated 
rats compared with sham animals (P=0.002). Three days 
pretreatment with Pel (10 mg/kg) in Aβ + Pel caused a 
significant increase in STL (P=0.02) compared with the 
Aβ group. Aβ + Pel + Anti Eα (P=0.003) and Aβ + Pel + 
Anti Eβ (P=0.003) groups followed the same track. 
Compared with Aβ + Pel, STL has not been changed 
among Aβ + Pel + Anti Eα (P=0.11) and Aβ + Pel + 
Anti Eβ (P=0.41) groups. 
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Discussion 
 
In the presented study, we investigated the potential 
memory-enhancing and the estrogenic receptor role of 
oral Pel pretreatment in an Aβ25–35 rat model of AD. Our 
findings show that bilateral CA1 hippocampal 
microinjections of Aβ25–35 caused significant memory 
loss in passive avoidance task paradigm. This finding is 
in agreement with similar studies in which bilateral CA1 
intrahippocampal microinjections of Aβ25-35 fragment 
produced reactive oxygen species followed by oxidative 
stress insults, neuronal degeneration and cell loss of the 
pyramidal cells affecting memory loss in rats (3). 
In passive avoidance performance, we found that 
bilateral CA1 hippocampal Aβ25-35 microinjections 
before the training phase of the classical one-trial 24-
hour foot shock avoidance application could effectively 
lengthen STL compared to control animals. This 
suggested that the substance was negatively affected 
long-term memory (LTM) while keeping IL untouched 
in all experimental groups. Pretreatment with Pel in the 
Aβ25-35 group could ameliorate defective LTM without 
disturbing normal ambulatory scenario even after about 
one month.  
Estrogen and its receptor modulators have shown to 
have a neuroprotective role in neurodegenerative 
conditions such as stroke, AD, and Parkinson disease. 
Although the exact mechanisms of this neuroprotection 
have not been exactly clarified, some leading 
possibilities have been addressed in the literature (24).  
Coadministration of α and β estrogen antagonists 
with Pel in the Aβ25-35 group could not change LTM in 
passive avoidance task performance. This stresses on the 
existence of estrogen derivative neuroprotection on 
LTM through other available mechanisms than typical 
estrogen receptors (ERs). ERs are largely spread over 
some memory related areas of the brain like the 
hippocampus, frontal cortex and amygdala (25). 
Estrogens’ neuroprotection may mediate mainly via ER-
dependent of genomic (nuclear) and non-genomic 
(extranuclear) and ER-independent pathways. In non-
genomic pathway, this may be achieved via G protein-
coupled receptor and tyrosine kinase receptor activations 
plus membrane fluidity alteration, K+ channel opening, 
and Ca+2 influx. The ER- independent estrogen 
neuroprotection is mainly attained through free radical 
scavenging, neuronal excitability and neurotransmission 
changes (26).  
Flavonoids can apply their neuroprotection in 
neurodegenerative diseases and aging via other different 
ways among which neuronal anti-inflammatory is a 
matter of vast studies (27). Pel has shown its own anti-
inflammatory effects when used in pro-inflammatory 
conditions such as macrophage exposure to 
lipopolysaccharide. The effect is mainly mediated by 
inducible nitric oxide synthase (iNOS) suppression and 
nuclear factor-κB (NF-κB), and signal transducer and 
activator of transcription 1 (STAT-1) inhibition (28-30). 
Although the studies showing parent anthocyanin anti-
inflammatory response in neuronal architecture are 
rather limited (31), their intestinal metabolites and 
bacterial bowel derivatives have shown to be effective in 
neuronal anti-inflammatory conditions (27). 
Anthocyanins antihypertensive and endothelial 
related relaxatory effects have shown in animals under a 
high cholesterol food protocol (13). This is basically 
mediated through bilitranslocase, an endothelial plasma 
membrane flavonoid transporter with vasodilatory 
properties (30). Therefore, improved blood flow 
especially in the hippocampal region following Pel use 
may stimulate neurogenesis and memory function. 
Moreover, increased dendritic spine density and 
morphology repair may also improve neuronal 
connectivity and memory performance (32). This would 
also be considered as another possible explanation for 
memory enhancing effects of ER agonists as Pel. 
Anthocyanin cellular responses can also be governed 
through signaling cascades such as phosphoinositide 3-
kinase (PI3K)/Akt, mitogen-activated protein kinase 
(MAPK), the indirect mammalian target of rapamycin 
(mTOR). Cell growth initiation through various 
regulatory pathways and pro-apoptotic molecules 
inactivation-like Bad to promote cell survival (18,30,33) 
are other presumptive ways that Pel may adopt to carry 
its positive memory effects. 
In conclusion, in this study results from passive 
avoidance test paradigm showed that three days oral Pel 
pretreatment (10 mg/kg) could reverse Aβ25-35 induced 
memory disturbance via ERs independent pathways. 
Targeting different pathological mechanisms, Pel would 
be one of the valuable natural substitutes for estrogen to 
prevent age-related cognitive changes and memory 
deficit states like AD. However, more studies should be 
done to show its exact mechanisms and other beneficial 
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